B-cell malignancies, such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) afflict 150,000 people in the seven major markets each year.
MOR208 is currently being evaluated as monotherapy in a phase 2a trial in relapsed/refractory patients with four different subtypes of NHL. Additionally, MorphoSys’s partner the Ohio State University is evaluating MOR208 in combination with lenalidomide in an investigator-sponsored trial phase 2 trial in CLL patients.
In 2015, MorphoSys plans to initiate two phase 2 clinical trials evaluating combinations of MOR208 with lenalidomide and bendamustine in diffuse large B-cell lymphoma (DLBCL). Additionally, a new investigator-sponsored pediatric trial using MOR208 in combination with an immune cell transplantation for children with ALL is in preparation.